Xeris Biopharma Holdings, Inc. (XERS) स्टॉक विश्लेषण

कंपनी का अवलोकन

Xeris Biopharma Holdings, Inc. operates as a commercial-stage biopharmaceutical entity headquartered in Illinois, dedicated to the development and commercialization of therapies targeting chronic endocrine and neurological conditions. The company functions within the Healthcare sector, specifically the Biotechnology industry, where it focuses on delivering specialized medical solutions such as Gvoke, a ready-to-use liquid-stable glucagon designed for the treatment of severe hypoglycemia in pediatric patients. As of the latest data, the company holds a market capitalization of $1.02B and generates annual revenue of $291.84M, employing a workforce of 435 individuals. These valuation and revenue figures indicate that Xeris occupies a mid-to-large cap position within the biotechnology landscape, possessing sufficient scale to fund R&D operations while maintaining a significant employee base to support its specialized therapeutic pipeline.

वित्तीय स्वास्थ्य

The company reported a total revenue of $291.84M over the trailing twelve months, with a net income of $554,000 and an EBITDA of $37.05M. The substantial disparity between the $291.84M in revenue and the $554,000 in net income highlights a cost structure characterized by high operating expenses relative to top-line sales, resulting in a profit margin of only 0.2%. Despite the low net income, the company generates $25.97M in free cash flow, which provides essential financial flexibility to fund ongoing research initiatives and operational expenditures without relying solely on external financing. The gross margin stands at 85.4%, reflecting the high value and low variable cost structure typical of biotechnology products, while the operating margin of 19.5% suggests that overhead costs remain a significant portion of revenue. The balance sheet shows a cash balance of $111.04M against total debt of $258.10M, creating a leverage situation where debt exceeds liquid assets. This capital structure is supported by a debt-to-equity ratio of 1885.44, indicating a highly leveraged position that amplifies financial risk under adverse market conditions. Liquidity is managed efficiently, as evidenced by a current ratio of 2.19, which signifies that the company holds more than double the current assets needed to cover its short-term liabilities. Return on equity is listed as N/A, while the return on assets is 4.4%, revealing that the company generates modest returns on its asset base despite the heavy debt load.

मूल्यांकन आकलन

Valuation metrics for Xeris Biopharma Holdings, Inc. show a trailing P/E ratio of N/A due to minimal net income, contrasted with a forward P/E of 15.98. The discrepancy between the absence of a trailing P/E and the existence of a forward P/E implies that the market expects significant earnings growth to materialize in future periods to justify current share prices. The price-to-book ratio is recorded at 72.20, which indicates that the market values the company at a substantial premium over its book value, likely reflecting the high intangible value of its intellectual property and pipeline potential. Alternative valuation metrics include a price-to-sales ratio of 3.50 and an EV/EBITDA of 31.52, suggesting that investors are pricing the stock based on sales multiples and enterprise value relative to cash flow rather than traditional earnings multiples. The stock's price volatility is contextualized by a 52-week high of $10.08 and a 52-week low of $3.81. The current trading price sits within this range, reflecting market sentiment that has fluctuated significantly over the past year. Additionally, the beta value of 0.99 indicates that the stock's price volatility generally moves in tandem with the broader market, exhibiting neither extreme aggression nor defensiveness relative to the overall market index.

Growth & Income

The company demonstrated a robust revenue growth rate of 42.8% year-over-year, while earnings growth is listed as N/A due to the low absolute earnings figure. The fact that earnings growth is not applicable while revenue expands rapidly implies that the company is prioritizing top-line expansion and market share acquisition over immediate profitability enhancement. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all generated earnings are reinvested into research, development, and commercialization efforts rather than being distributed to shareholders. This reinvestment strategy is common in the biotechnology sector, where capital allocation toward innovation is critical for long-term survival and success. The overall growth and income profile characterizes Xeris as a capital-intensive growth company that currently forgoes income distribution to fuel its strategic objectives and expand its therapeutic portfolio.